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“ . . . the plague bacillus never dies or disappears for
good;  . . .  it bides its time in bedrooms, cellars, trunks,
and bookshelves; and perhaps the day would come when,
for the bane and the enlightening of men, it would rouse
up its rats again and send them forth to die in a happy city.”
Albert Camus, The Plague.
Few other pathogens have caused as much devastation in
human history as 
 
Yersinia pestis
 
, the etiologic agent of the
plague, or the Black Death, as the disease was aptly named
in the Middle Ages. 
 
Y. pestis
 
 is generally transmitted
through the bites of the rat flea 
 
Xenopsylla cheopis
 
, while the
two other related pathogenic 
 
Yersinia
 
 species, 
 
Y. pseudotu-
berculosis
 
 and 
 
Y. enterocolitica
 
, are food-borne pathogens that
cause various gastrointestinal syndromes (1). All three spe-
cies of 
 
Yersinia
 
 are pathogenic for humans and rodents and,
despite differences in the routes of entry into the host, all
three infect lymphoid tissues and organs. The pathogenicity
of 
 
Yersinia spp.
 
 largely results from the ability to resist innate
host defense mechanisms such as phagocytosis and the in-
duction of inflammatory responses by macrophages and
neutrophils. 
 
Yersinia
 
 achieves this resistance by injecting
into host cells effector proteins that can manipulate or in-
hibit normal immune responses.
Like many other gram-negative bacterial pathogens of
animals and plants, 
 
Yersinia
 
 employs a specialized secretory
apparatus called the type III secretion system (TTSS) to in-
teract with host cells (1, 2). The TTSS is a multicomponent
secretion machine that injects specialized proteins (TTSS
effectors) into the cytosol of the host cell where they inter-
 
act with a variety of host proteins and thus manipulate cellu-
lar behavior in ways that ultimately benefit the pathogen
(3). The effector proteins (collectively referred to as Yops–
Yersinia outer membrane proteins) and the proteins com-
prising the TTSS are all encoded on a 70-kb plasmid (2).
The cellular functions of the Yops are currently under in-
tense study and fall into two general categories: proteins fa-
cilitating the translocation of Yops into the host cells, and
those actually secreted into the cytosol (1, 2). Notably,
YopD, YopB, and LcrV (low calcium response protein V)
appear to operate in the translocation of other Yops into
the cytosol whereas YopE, YopH, YopJ (Yop P in 
 
Y. en-
terocolitica
 
), YopM, YopO, and YopT function within the
host cell (1, 2). The Yop proteins are 
 
Yersinia
 
 virulence fac-
tors that can interfere with phagocytosis, inhibit the antimi-
crobial oxidative burst, inhibit the production of inflamma-
tory cytokines, such as TNF-
 
 
 
, and promote apoptosis in
macrophages and neutrophils (1, 2). Like TTSS effectors of
other bacterial pathogens, Yops function by mimicking ac-
 
tivities of cellular proteins and either activate or inhibit
cellular processes to promote the pathogen’s survival and
replication (4).
An article in this issue by Sing et al. (5) suggests a novel
and unexpected function for the 
 
Yersinia
 
 virulence factor
known as LcrV. LcrV was characterized some 50 yr ago as
it is the major antigen of 
 
Yersinia
 
 (6, 7). In addition to its
function in TTSS-mediated protein translocation, LcrV can
also be secreted into the environment (6). Secreted LcrV
has been previously shown to down-regulate host protec-
tive immune responses and this LcrV-mediated immune
evasion is due to the ability of LcrV to induce IL-10 pro-
duction by macrophages (8). Thus, pretreatment of wild-
 
type peritoneal macrophages with recombinant LcrV (rLcrV)
 
led to an inhibition of zymosan-induced TNF-
 
 
 
 produc-
tion. This effect was IL-10 dependent because it could be
reversed by neutralizing antibodies specific to IL-10 (but
not IL-4 or TGF-
 
 
 
: two other cytokines known to in-
hibit inflammatory responses of macrophages). Moreover,
IL-10–deficient macrophages could still produce TNF-
 
 
 
after rLcrV pretreatment (8). Not surprisingly then, IL-10–
deficient mice were found to be more resistant to 
 
Y. entero-
colitica
 
 infection than wild-type mice (8). Following these
findings, Sing et al. sought to identify cellular receptors re-
sponsible for LcrV-induced IL-10 production. Surprisingly,
these receptors turned out to be CD14 and TLR2 (5).
The Toll-like receptors (TLRs) comprise a family of
signaling receptors involved in innate immune recogni-
tion of microbes (9, 10). When TLRs engage their micro-
bial ligands, they activate signaling pathways including
nuclear factor (NF)-
 
 
 
B and mitogen-activated protein
(MAP) kinases which leads to the production of proin-
flammatory cytokines such as TNF-
 
 
 
, IL-6, and IL-12 as
well as to the induction of microbicidal mechanisms. In
addition to activating effector cells of the innate immune
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system (such as macrophages and neutrophils), TLRs turn
on many genes required for the initiation of pathogen-
specific adaptive immune responses (9, 10). Indeed, mice
deficient in individual TLRs or their signaling compo-
nents are highly susceptible to a variety of microbial infec-
tions (10).
The TLRs belong to a class of pattern recognition recep-
tors (PRRs) because they recognize conserved molecular
signatures (or patterns) common to entire classes of micro-
organisms. These molecular signatures or pathogen associ-
ated molecular patterns (PAMPs) are essential for microbial
survival and are therefore highly conserved. It is this evolu-
tionary conservation of PAMPs that makes them perfect
targets for innate immune recognition which must rely on
a limited number of germline-encoded receptors (11). The
PAMPs recognized by TLRs are representative of bacte-
rial, fungal, and viral pathogens including the TLR4
ligand, LPS (product of gram-negative bacteria), the TLR2
ligands, peptidoglycan and zymosan (gram positive bacteria
and yeast cell wall products, respectively), the TLR9
ligand, unmethylated CpG DNA (presumably of bacterial
and viral origin), the TLR3 ligand, double-stranded RNA
(viral product), and the TLR5 ligand, flagellin (bacterial
protein; references 12–20). Some TLRs require accessory
proteins for ligand recognition. For example, CD14 func-
tions as a ligand binding accessory receptor protein that aids
TLR2 and TLR4 in recognition of peptidoglycan and LPS,
respectively (9, 10).
It is important to note that unlike virulence factors, mi-
crobial products recognized by TLRs are not unique to
pathogens and evolved to perform physiological functions
unrelated to host-pathogen interactions. Indeed, most, if
not all, PAMPs existed long before TLRs or the host.
Conversely, virulence factors evolved as a result of adapta-
tion to the host; they manipulate cellular proteins in order
to increase the adaptive fitness of the pathogen in the
unique environment provided by the host (Table I).
Therefore, interaction of LcrV with TLR2 should not be
mistaken for pattern recognition. Rather, it is an example
of a virulence factor that appears to exploit the pattern rec-
ognition system to the advantage of the pathogen. The de-
tails of the mechanism of this manipulation, however, re-
main unclear.
 
Table I.
 
Comparison of PAMPs and Virulence Factors
 
PAMPs Virulence Factors
Invariant products of conserved
metabolic pathways
Differ between
different pathogens
Evolved to perform essential
physiological functions of
microorganisms
Evolved as a result
of adaptation to the host
Not unique to pathogens.
Produced by all
microorganisms of a
given class
Unique to pathogens
Targets of innate
immune recognition
Not recognized directly by
PRRs. Some virulence factors
may interact with PRRs to
manipulate the host innate
immune response
Figure 1. Yersinia employ Yop
effector proteins to inhibit the
antimicrobial functions of mac-
rophages. The Toll-like recep-
tor family of proteins recognizes
PAMPs expressed by bacteria
and initiates a signaling cascade
leading to activation of mac-
rophages.  Yersinia injects effec-
tor proteins (Yops) via the type
III secretion system into host
macrophages. Injected Yops in-
hibit phagocytosis, inflammation,
and the synthesis of antibacterial
proteins. One of the Yops, LcrV,
is secreted and can act at a dis-
tance. LcrV utilizes TLR2 to in-
duce the production of the anti-
inflammatory cytokine, IL-10,
further dampening the innate
immune response. 
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Sing et al. found that secretion of IL-10 in response to
rLcrV was abrogated in CD14 and TLR2-deficient macro-
phages. Further, rLcrV was shown to activate an NF-
 
 
 
B
reporter gene in CD14 and TLR2-transfected cells (5). As
suggested by previous studies (8), the LcrV homologue
from 
 
P. aeroginosa
 
 (PcrV) had no TLR2-inducing activity.
Remarkably, the TLR2 stimulating region of LcrV maps to
a short 19 amino acid long NH
 
2
 
-terminal sequence that is
divergent between LcrV and PcrV (8). Finally, the implica-
tion that LcrV triggers IL-10 secretion through CD14/
TLR2 to downmodulate the immune response was further
substantiated by the fact that TLR2-deficient mice were
actually more resistant to 
 
Y. enterocolitica
 
 infection than
wild-type animals (5).
This provocative work provides one of the first examples
of a microbial strategy of immune evasion based on manip-
ulation of the TLR system. However, there are several lim-
itations to this study that make interpretation of some of
the results difficult and these issues will need to be resolved
in the future. First, the immunosuppressive effect of LcrV
was tested with regard to TNF-
 
 
 
 production induced by
zymosan. As 
 
Yersinia
 
 are gram-negative bacteria, a more bi-
ologically relevant stimulus would have been LPS. Never-
theless, the main source of confusion is the fact that when
triggered by its microbial ligands, TLR2, like other TLRs,
induces the production of pro-inflammatory cytokines,
such as TNF-
 
 
 
, IL-6, and IL-12 (19, 21). It remains to be
determined whether LcrV induces these cytokines in addi-
tion to IL-10. If LcrV promotes IL-10 secretion without
inducing a proinflammatory response, this would imply
that LcrV initiates a different signaling pathway than that
triggered by other TLR2 ligands. Although it is formally
possible, it seems highly unlikely that that could be the
case. TLR2 functions as a heterodimer with either TLR1
or TLR6 (22–25), and possibly with some other, as yet
uncharacterized TLRs. Different ligands engage distinct
TLR2 heterodimers: tripalmitoylated lipoproteins, for ex-
ample, engage a TLR2/TLR1 complex, whereas pepti-
doglycan and dipalmitoylated lipoproteins, such as the ones
found in mycoplasma, are detected via a TLR2/TLR6
complex (22–25). Conceivably, LcrV could engage TLR2
with another TLR, and this complex could induce the IL-
10 gene, rather than the genes encoding proinflammatory
cytokines (Fig. 1). This possibility could easily be addressed
by a careful comparison of IL-10 and TNF-
 
 
 
 induction by
LcrV versus peptidoglycan or lipoproteins. Unfortunately,
without such comparison it is difficult to conclude whether
there is something unique in the way LcrV activates TLR2.
Another salient issue that these experiments would ad-
dress is whether the immunosuppressive activity of LcrV is
related to the phenomenon of LPS tolerance. When mac-
rophages are stimulated with LPS, they become refractory
to a second LPS stimulation. This unresponsiveness to sec-
ondary LPS stimulation (known as “LPS tolerance”) is
maximal at around 24 h and subsides at longer time points.
Although first described for LPS, this tolerance applies to
other TLR ligands as well (26, 27). The mechanisms of tol-
erance are not completely understood and appear to be dis-
tinct for different TLRs (26, 27). Two features of LcrV ac-
tivity suggest that LcrV-induced inhibition of TNF-
 
 
 
production is not due to tolerance induction via TLR2.
First, the time sufficient for blocking zymosan-induced
TNF-
 
 
 
 production (3 h) is much less than what is required
for the induction of maximal unresponsiveness due to a tol-
erance mechanism (24 h). Second, tolerance to TLR2 and
TLR4 ligands is known to be IL-10 independent (27),
whereas LcrV effects appear to be completely IL-10 depen-
dent. A direct comparison of the effect of LcrV with the ef-
fects of other TLR ligands on macrophage responsiveness
would be necessary to determine whether LcrV engages a
signaling pathway distinct from other TLR ligands.
Many, if not all, TLR ligands can induce IL-10 secretion
by macrophages as a part of a negative feedback control that
limits the inflammatory response. This IL-10 induction,
however, is typically delayed compared with the induction
of proinflammatory cytokines. Therefore, the kinetics of
IL-10 production induced by LcrV and by other TLR2 (as
well as TLR4) ligands would also be very informative.
These questions notwithstanding, this study describes a
very exciting finding of a novel mechanism of immune
evasion that contributes to the virulence of one of the
deadliest pathogens known to humankind. Without a
doubt, many more examples of microbial interference with
TLRs and their signal transduction pathways will be dis-
covered, and these will help both to understand the patho-
gen’s virulence mechanisms and to elucidate the complex-
ity of innate immune recognition.
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